贝伐单抗联合培美曲塞加卡铂二线治疗晚期非小细胞肺癌的临床观察被引量：11

Clinical Observation of Second Line Treatment of Bevacizumab Combined with Pemetrexed and Carboplatin for Advanced Non-Small Cell Lung Cancer

原文传递

导出

摘要目的:观察贝伐单抗联合培美曲塞加卡铂二线治疗晚期非小细胞肺癌(NSCLC)的疗效及不良反应。方法:30例晚期NSCLC患者采用随机数字表法分为试验组(10例,贝伐单抗15mg·kg-1+培美曲塞500mg·m-2+卡铂AUC6)与对照组(20例,培美曲塞500mg·m-2+卡铂AUC6),21d为1个周期。完成2个周期以上评价疗效和不良反应。结果:试验组与对照组的疾病控制率分别为80.0%、40.0%(P<0.05),中位无进展生存期分别为4.7、3.2个月(P<0.05),有效率分别为20.0%、5.0%(P>0.05),中位生存期分别为9.2、7.9个月(P>0.05)。2组主要不良反应比较,差异无统计学意义(P>0.05)。结论:贝伐单抗联合培美曲塞加卡铂二线治疗晚期NSCLC在疾病控制率和中位无进展生存期方面优于培美曲塞加卡铂方案,且未加重不良反应,患者能够耐受。 OBJECTIVE: To observe the clinical efficacy and adverse drug reaction of second line treatment of bevacizumab combined with pemetrexed and carboplatin for advanced non-small cell lung cancer(NSCLC). METHODS: 30 advanced NSCLC patients were divided into experimental group (10 cases, bevacizumab 15 mg·kg-1 +pemetrexed 500 mg·m-2+carboplatin AUC6) and control group (20 cases, pemetrexed 500 mg·m-2+ carboplatin AUC6) by the method of random number table with 21 days as one cycle. Therapeutic efficacy and advers...

作者周立霞哈敏文

机构地区辽宁医学院

出处《中国药房》 CAS CSCD 北大核心 2011年第6期529-531,共3页 China Pharmacy

关键词非小细胞肺癌贝伐单抗培美曲塞卡铂化疗 Non-small cell lung cancer Bevacizumab Pemetrexed Carboplatin Chemotherapy

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1梅同华,徐小杰.TP与NP方案治疗晚期非小细胞肺癌的疗效比较[J].中国药房,2005,16(2):127-128. 被引量：15
2Manegold C,Pawel J von,Zatloukal P,et al.Ran-domised,double-blind multicenter phaseⅢstudy of bev-acizumab in combination with cisplatin and gemcitabine inno nc-hseqmuaomthoeurasp nyo-nna-s?vmea plla tcieelnl tslu wngit hc aandcvear (ncNedS-oCr LreCc)u:rrBenOt17704. Journal of Clinical Oncology . 2007
3Ferrara N.Vascular endothelial growth factor: basic science and clinical progress. Endocrine Reviews . 2004
4Herbst R,O‘Neill V,Fehrenbacher L,et al.A phase Ⅱ,multicenter,randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or. Journal of Clinical Oncology . 2006
5Ferrara N.Vascular endothelial growth factor as a target for anticancer therapy. The Oncologist . 2004
6Mohammed KA,Nasreen N,Hardwick J,et al.Bacterial induction of pleural mesothelial monolayer barrier dysfunction. American Journal of Physiology Lung Cellular and Molecular Physiology . 2001
7FERRARA N,HILLAN K J,NOVOTNY W.Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications . 2005
8P Therasse,SG Arbuck,EA Eisenhauer,et al.New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute . 2000
9Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, The . 2006

二级参考文献8

1Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment [ J ] . Cancer, 1981,47(1) : 207.
2Ormrod D, Spencer CM .Topotecan :a review of its efficacy in small cell lung cancer[J]. Drugs, 1999,58(3) :saa.
3Mitsui I ,Kumazawa E ,Hirota Y .A new water soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and invivo [J ] .Jpn J Cancer Res, 1995,86(8) : 776.
4Potier P.History of the discovery of nacelbine. In pierre fabre oncology, eds.Navelbine. Update and New Trends [ M] .France : John Libbery Eurotext Ltd, 1991:4-6.
5Depierre A,Jacoulet P,Garnier G.Efficacy of navelbine and vinca alkaloids in the treatment of non- small cell lung cancer(NSCLC) . IN:Pierre Fabra Oncologic,eds.Navelbine. Update and New Trends [M]. Isted France:John Libbery Eurotext Ltd, 1991:133.
6张湘茹,孙燕,孔维红,周生余,冯奉仪.去甲长春花碱加顺铂治疗晚期非小细胞肺癌42例[J].中华肿瘤杂志,1998,20(1):60-62. 被引量：527
7董梅,冯奉仪.抗癌新药拓扑替康研究新进展[J].国外医学（肿瘤学分册）,2001,28(1):75-79. 被引量：17
8刘刚,杨和平,胡建林,王政惠.拓扑替康联合顺铂治疗晚期肺鳞癌的初步临床研究[J].重庆医学,2002,31(9):786-788. 被引量：5